Emerging Drug Treatments for Solid Tumours

[1]  P. Workman,et al.  Unusually marked hypoxic sensitization to indoloquinone E09 and mitomycin C in a human colon‐tumour cell line that lacks DT‐diaphorase activity , 2007, International journal of cancer.

[2]  R. Goldberg,et al.  Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Niitani,et al.  147 Phase II studies of a 60 mg/m2 dose of docetaxel in patients with non-small cell lung cancer , 1997 .

[4]  S. Rodenhuis,et al.  Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. , 1997, Seminars in oncology.

[5]  D. Dunlop,et al.  Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results. , 1996, Seminars in oncology.

[6]  T. Chou,et al.  Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Barakat,et al.  Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. A. Robinson,et al.  Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Eisenhauer,et al.  Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Wanders,et al.  Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  R. Pirker,et al.  Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  S. Lipsitz,et al.  Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) , 1995, Investigational New Drugs.

[13]  J. Verweij,et al.  Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks , 1995, Cancer Chemotherapy and Pharmacology.

[14]  A. Gouyette,et al.  Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  G. Rosner,et al.  Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. McLeod,et al.  Topoisomerase I and II activity in human breast, cervix, lung and colon cancer , 1994, International journal of cancer.

[17]  J B Vermorken,et al.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Barakat,et al.  Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Schwartz,et al.  Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Groshen,et al.  Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  D. Neuberg,et al.  Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Neijt,et al.  Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. , 1994, Journal of the National Cancer Institute.

[23]  L. Grochow,et al.  Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Sculier,et al.  Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. , 1994, Seminars in oncology.

[25]  S. Baker,et al.  Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Thigpen,et al.  Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Bezwoda,et al.  Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Kaye.  Gemcitabine: current status of phase I and II trials. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Wanders,et al.  Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) , 1994, British Journal of Cancer.

[30]  J. Wanders,et al.  Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. , 1994, British Journal of Cancer.

[31]  C. Sternberg,et al.  Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study. , 1994, British Journal of Cancer.

[32]  M. Ratain,et al.  Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.

[33]  M. Piccart,et al.  A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck , 1994 .

[34]  J. Verweij,et al.  Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  M. Piccart,et al.  Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck , 1994 .

[36]  M. Piccart,et al.  A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  J. Verweij,et al.  Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult , 1994 .

[38]  J. Verweij,et al.  Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. , 1994, Journal of the National Cancer Institute.

[39]  L. Dirix,et al.  Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns. , 1994, Anti-cancer drugs.

[40]  G. Adams,et al.  Bioreductive drugs for cancer therapy: the search for tumor specificity. , 1994, International journal of radiation oncology, biology, physics.

[41]  P. Workman,et al.  Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. , 1994, International journal of radiation oncology, biology, physics.

[42]  K. Eguchi,et al.  Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. , 1994, Cancer research.

[43]  T. Tsuruo,et al.  Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells. , 1994, Cancer research.

[44]  M. Piccart,et al.  Potential Role of Oral Anthracyclines in Older Patients with Cancer , 1994, Drugs & aging.

[45]  J. Ajani,et al.  Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  G. Peters,et al.  Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. , 1994, Biochemical pharmacology.

[47]  G. Powis.  Recent Advances in the Development of Anticancer Drugs that Act against Signalling Pathways , 1994, Tumori.

[48]  C. Hennequin,et al.  Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. , 1994, Cancer research.

[49]  P. Hérait,et al.  Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. , 1994, Journal of the National Cancer Institute.

[50]  M. Potměšil,et al.  Camptothecins: from bench research to hospital wards. , 1994, Cancer research.

[51]  W. Furman,et al.  Phase I study of topotecan for pediatric patients with malignant solid tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  G. Peters,et al.  In-vitro schedule-dependency of eo9 and miltefosine in comparison to standard drugs in colon-cancer cells. , 1994, International journal of oncology.

[53]  H. Hochster,et al.  Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  R. Ozols,et al.  Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. , 1994, Cancer research.

[55]  L. Kalish,et al.  Phase II study of topotecan in metastatic non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Perez,et al.  Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. , 1994, Cancer research.

[57]  S. Singh,et al.  Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue. , 1994, British Journal of Cancer.

[58]  H. Hollema,et al.  Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. , 1994, Cancer research.

[59]  E. Eisenhauer,et al.  Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  L. Grochow,et al.  Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. , 1994, Cancer research.

[61]  D. V. Von Hoff,et al.  Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro. , 1994, Journal of the National Cancer Institute.

[62]  L. Pendyala,et al.  In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. , 1993, Cancer research.

[63]  M. Christian,et al.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  M. Millward,et al.  Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. , 1993, Journal of the National Cancer Institute.

[65]  M. Bibby,et al.  Evaluation of the cytotoxicity of the indoloquinone eo9 in a human colon adenocarcinoma model. , 1993, International Journal of Oncology.

[66]  C. Hudis,et al.  Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  E K Rowinsky,et al.  Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  H. Hansen,et al.  Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  Dirk Schrijvers,et al.  Coping with toxicities of docetaxel (TaxotereTM) , 1993 .

[70]  P. O'Brien,et al.  Contrasting molecular cytotoxic mechanisms of mitomycin C and its two analogs, BMY 25282 and BMY 25067, in isolated rat hepatocytes. , 1993, Biochemical pharmacology.

[71]  T. Taguchi,et al.  Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  A. Bodley,et al.  A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. , 1993, Cancer research.

[73]  G. Schwartz,et al.  Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. , 1993, Journal of the National Cancer Institute.

[74]  R. Winn,et al.  Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[75]  T Anderson,et al.  Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. , 1993, Journal of the National Cancer Institute.

[76]  F. Balis,et al.  Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. , 1993, Cancer research.

[77]  M. Marty,et al.  Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. , 1993, Cancer research.

[78]  E K Rowinsky,et al.  The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.

[79]  D. Kerr,et al.  Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. , 1993, Cancer research.

[80]  H. Hansen,et al.  Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  E. Reed,et al.  Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin. , 1993, Cancer research.

[82]  D. V. Von Hoff,et al.  Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. , 1992, Journal of the National Cancer Institute.

[83]  D. Moore,et al.  Phase I trial of Taxotere: five-day schedule. , 1992, Journal of the National Cancer Institute.

[84]  G. Montay,et al.  Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. , 1992, Journal of chromatography.

[85]  M. Fukuoka,et al.  CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  C. Runowicz,et al.  Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  L. Kèlland,et al.  Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. , 1992, Cancer research.

[88]  L. Grochow,et al.  Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[89]  J. Riou,et al.  Effects of Taxotere on murine and human tumor cell lines. , 1992, Biochemical and biophysical research communications.

[90]  G. Weiss,et al.  A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days , 1992, Anti-cancer drugs.

[91]  C. O'Neill,et al.  Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. , 1992, Cancer research.

[92]  A. Gescher.  Towards selective pharmacological modulation of protein kinase C--opportunities for the development of novel antineoplastic agents. , 1992, British Journal of Cancer.

[93]  J. Karaszkiewicz,et al.  Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. , 1992, Cancer research.

[94]  F. Ognibene,et al.  Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  H. Ohmatsu,et al.  Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. , 1992, Journal of the National Cancer Institute.

[96]  Y. Cheng,et al.  Characterization of camptothecin-resistant Chinese hamster lung cells. , 1992, Biochemical pharmacology.

[97]  D. Vos,et al.  Exceptionally high in vitro antitumor activity of substituted triphenyltin benzoates including salicylates against a human mammary tumor, MCF‐7, and a colon carcinoma, WiDr , 1992 .

[98]  L. Grochow,et al.  Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  S. Hilsenbeck,et al.  Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells , 1992, Anti-cancer drugs.

[100]  A. Bitonti,et al.  Inhibition of experimental metastasis and cell adhesion of B16F1 melanoma cells by inhibitors of protein kinase C. , 1992, Cancer research.

[101]  Y. Miura,et al.  Effects of CPT‐11 in combination with other anti‐cancer agents in culture , 1992, International journal of cancer.

[102]  A. Reinberg,et al.  A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer , 1992, Cancer.

[103]  N. Saijo,et al.  Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. , 1992, Cancer research.

[104]  G. Hortobagyi,et al.  Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. , 1991, Journal of the National Cancer Institute.

[105]  G. Hofmann,et al.  Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). , 1991, Cancer research.

[106]  J. Correia,et al.  Effects of antimitotic agents on tubulin-nucleotide interactions. , 1991, Pharmacology & therapeutics.

[107]  R. Donehower,et al.  The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. , 1991, Pharmacology & therapeutics.

[108]  S. Akinaga,et al.  Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. , 1991, Cancer research.

[109]  M. Bissery,et al.  Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. , 1991, Cancer research.

[110]  E K Rowinsky,et al.  Sequences of taxol and cisplatin: a phase I and pharmacologic study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  M. Fukuoka,et al.  Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. , 1991, Journal of the National Cancer Institute.

[112]  H. Kuga,et al.  Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.

[113]  John D. Roberts,et al.  Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. , 1991, Cancer research.

[114]  W. Berdel.  Membrane-interactive lipids as experimental anticancer drugs. , 1991, British Journal of Cancer.

[115]  Berdel We.  Membrane-interactive lipids as experimental anticancer drugs. , 1991 .

[116]  H. Earl,et al.  A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  J. Koeller,et al.  A phase I trial of taxol given by a 6-hour intravenous infusion. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  J. Boehm,et al.  Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. , 1991, Journal of medicinal chemistry.

[119]  D. Burns,et al.  Lipid activation of protein kinase C. , 1991, The Journal of biological chemistry.

[120]  S. Mineishi,et al.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  D. Faulds,et al.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. , 1991, Drugs.

[122]  D. Guénard,et al.  Relationships between the structure of taxol analogues and their antimitotic activity. , 1991, Journal of medicinal chemistry.

[123]  D. Trump,et al.  A phase II study of taxol in patients with malignant melanoma , 1991, Investigational New Drugs.

[124]  H. Kantarjian,et al.  Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. , 1990, Cancer research.

[125]  T. Tsuruo,et al.  Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. , 1990, Cancer research.

[126]  N. Saijo,et al.  Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. , 1990, Cancer research.

[127]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.

[128]  L. Hertel,et al.  Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.

[129]  R. Benjamin,et al.  A phase II trial of taxol in metastatic melanoma , 1990, Cancer.

[130]  J. C. Houwelingen,et al.  Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer , 1990 .

[131]  L. Liu,et al.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.

[132]  D. Guénard,et al.  Application of the Vicinal Oxyamination Reaction with Asymmetric Induction to the Hemisynthesis of Taxol and Analogues. , 1989 .

[133]  P. Disaia,et al.  A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  D. Ettinger,et al.  Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. , 1989 .

[135]  D. Ettinger,et al.  Phase I and pharmacodynamic study of taxol in refractory acute leukemias. , 1989, Cancer research.

[136]  L. Kèlland,et al.  Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. , 1989, British Journal of Cancer.

[137]  Y. Nishizuka,et al.  The molecular heterogeneity of protein kinase C and its implications for cellular regulation , 1988, Nature.

[138]  G. Storme,et al.  Modification of cell surface carbohydrates and invasive behavior by an alkyl lysophospholipid. , 1988, Cancer research.

[139]  L. Grochow,et al.  Phase I trial of taxol in patients with advanced cancer. , 1987, Cancer treatment reports.

[140]  J. Willson,et al.  Phase I study of taxol administered as a short i.v. infusion daily for 5 days. , 1987, Cancer treatment reports.

[141]  T. Tanaka,et al.  Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. , 1987, Cancer research.

[142]  R. Lipton,et al.  Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  R. Lipton,et al.  Phase I clinical and pharmacokinetic study of taxol. , 1987, Cancer research.

[144]  F. Snyder,et al.  Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells. , 1986, Cancer research.

[145]  S. Goldfarb,et al.  Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). , 1983, The New England journal of medicine.

[146]  J Parness,et al.  Taxol binds to polymerized tubulin in vitro , 1981, The Journal of cell biology.

[147]  K. Crossin,et al.  Evidence that microtubule depolymerization early in the cell cycle is sufficient to initiate DNA synthesis , 1981, Cell.

[148]  P. Schiff,et al.  Taxol stabilizes microtubules in mouse fibroblast cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[149]  A. Otto,et al.  Cytoskeleton-disrupting drugs enhance effect of growth factors and hormones on initiation of DNA synthesis. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[150]  R. Andreesen,et al.  Selective destruction of human leukemic cells by alkyl-lysophospholipids. , 1978, Cancer research.

[151]  G M Edelman,et al.  Surface modulation in cell recognition and cell growth. , 1976, Science.

[152]  J. Bryan.  Biochemical properties of microtubules. , 1974, Federation proceedings.

[153]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[154]  Cancer Research , 1965, Nature.

[155]  D. Faulds,et al.  Idarubicin , 2012, Drugs.

[156]  C. Bokemeyer,et al.  Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[157]  W. Zeller,et al.  In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and-resistant rat ovarian tumors , 2004, Cancer Chemotherapy and Pharmacology.

[158]  David C. Smith,et al.  Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial , 2004, Cancer Chemotherapy and Pharmacology.

[159]  W. J. Vijgh,et al.  WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach , 2004, Cancer Chemotherapy and Pharmacology.

[160]  H. Burris,et al.  Preclinical and phase I trials of topoisomerase I inhibitors , 2004, Cancer Chemotherapy and Pharmacology.

[161]  J. Abbruzzese,et al.  Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine , 2004, Cancer Chemotherapy and Pharmacology.

[162]  L. Kèlland,et al.  Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and-resistant human ovarian carcinoma cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[163]  Y. Honma.  [Induction of differentiation of leukemia cells]. , 1998, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[164]  Jones Sf,et al.  Topoisomerase I inhibitors: topotecan and irinotecan. , 1996, Cancer practice.

[165]  G. Bonadonna,et al.  Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  J. Verweij,et al.  Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. , 1994, European journal of cancer.

[167]  G. Hortobagyi,et al.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance. , 1994, Drugs.

[168]  A. Crowe.  Antitumour activity of tin compounds , 1994 .

[169]  J. Wanders,et al.  Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. , 1994, European journal of cancer.

[170]  S. Aamdal,et al.  Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. , 1994, European journal of cancer.

[171]  R. Paridaens,et al.  Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. , 1994, European journal of cancer.

[172]  J. Verweij,et al.  Topoisomerase I inhibitors: topotecan and irenotecan. , 1994, Cancer treatment reviews.

[173]  S. Fricker.  Metal Compounds in Cancer Therapy , 1994, Springer Netherlands.

[174]  S. Seeber,et al.  Randomized Trial of Two Doses of Taxol in Metastatic Breast Cancer: An Interim Analysis , 1994 .

[175]  H. Hansen,et al.  Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine). , 1993, Cancer treatment reviews.

[176]  M. van Glabbeke,et al.  Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. , 1993, European journal of cancer.

[177]  J. Verweij,et al.  Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. , 1993, European journal of cancer.

[178]  W. Hong,et al.  Phase II study of topotecan in patients with non-small cell lung cancer , 1993 .

[179]  J. Double,et al.  EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. , 1993, European journal of cancer.

[180]  M. Piccart,et al.  Taxotere toxicity — Protective effects of premedication , 1993 .

[181]  R. Bukowski,et al.  Phase I study of WR-2721 and carboplatin. , 1993, European journal of cancer.

[182]  P. Hérait,et al.  High dose intensity of CPT-11 administered as single dose every 3 weeks: The instittut gustave roussy experience , 1993 .

[183]  C. Fellbaum,et al.  Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. , 1993, European journal of cancer.

[184]  S. Lippman,et al.  Phase I studies of gemcitabine , 1993 .

[185]  D. Neuberg,et al.  Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial. , 1993, Journal of the National Cancer Institute. Monographs.

[186]  L. Dirix,et al.  A phase I and pharmacokinetic trial of KW-2149, a mitomycin C analogue, in patients with solid tumours , 1993 .

[187]  J. Verweij,et al.  Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. , 1993, European journal of cancer.

[188]  S. Horwitz,et al.  Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.

[189]  Y. Nishiwaki,et al.  A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  G. Pettit.  The bryostatins. , 1991, Fortschritte der Chemie organischer Naturstoffe = Progress in the chemistry of organic natural products. Progres dans la chimie des substances organiques naturelles.

[191]  G. Snow,et al.  Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. , 1991, Cancer research.

[192]  A. Einzig,et al.  Phase II trial of taxol in patients with metastatic renal cell carcinoma. , 1991, Cancer investigation.

[193]  J. Boehm,et al.  Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity , 1991 .

[194]  L. Kèlland,et al.  The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[195]  Y Nishizuka,et al.  The protein kinase C family: heterogeneity and its implications. , 1989, Annual review of biochemistry.

[196]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[197]  D. Guénard,et al.  Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues , 1989 .

[198]  J. Glick,et al.  Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy. , 1988, Pharmacology & therapeutics.

[199]  L. Shaw,et al.  Can WR-2721 be improved upon? , 1988, Pharmacology & therapeutics.

[200]  L. Grochow,et al.  High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. , 1987, Cancer treatment reports.

[201]  M. Mareel,et al.  Antiinvasive effect of racemic 1-O-octadecyl-2-O-methylglycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro. , 1985, Cancer research.

[202]  R. Andreesen,et al.  Synthetic alkylphospholipid analogues: a new class of antitumor agents , 1985 .

[203]  J. Kuo.  Phospholipids and cellular regulation , 1985 .

[204]  J. Manfredi,et al.  Taxol: an antimitotic agent with a new mechanism of action. , 1984, Pharmacology & therapeutics.

[205]  W. Rose,et al.  Antitumor activity and toxicity of cisplatin analogs. , 1982, Cancer treatment reports.

[206]  R. Andreesen,et al.  Alkyl-lysophospholipid induced suppression of human lymphocyte response to mitogens and selective killing of lymphoblasts. , 1980, Immunobiology.

[207]  O. Westphal,et al.  Lysolecithin analogs. A new class of immunopotentiators with antitumor activity. Abstr. , 1976 .